ENZBinactive

ENZYMEBIOSYSTEMS

Healthcare·Oncology·Pre-clinical
Oncology

ENZYMEBIOSYSTEMS (ENZB): 2 pipeline candidates · ~33 mo cash runway. Updated within the last hour.

6.4/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway9.1

32.9 months

Financial Health10.0

D/E 0.01 · 0% dilution

Pipeline Maturity2.0

Lead: Preclinical

Pipeline Breadth4.6

2 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for ENZYMEBIOSYSTEMSacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

—

Cash

$391K

Quarterly Burn

$36K

Runway

32.9 mo

Revenue

—

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Mar 2029
Today~36 mo out
Catalyst within runway

Pipeline (2 candidates)

DrugPhase
amooraninPreclinical
amooranin-mePreclinical

Frequently asked questions

How many drug candidates are in ENZYMEBIOSYSTEMS's pipeline?

ENZYMEBIOSYSTEMS (ENZB) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is ENZYMEBIOSYSTEMS's lead drug candidate?

ENZYMEBIOSYSTEMS's most advanced tracked candidate is amooranin (Preclinical) for Hepatocellular carcinoma.

What is ENZYMEBIOSYSTEMS's cash runway?

Based on its most recent reported cash balance and quarterly burn rate, ENZYMEBIOSYSTEMS has approximately 32.9 months of cash runway.

Get the full picture on ENZYMEBIOSYSTEMS

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar